Presented by expert speakers, our digital workshops will give you advance insight into topics that will be covered at the event.
Can’t make the date? Still register to receive the webinar recording afterwards.
Drug Discovery Digital Workshop
Targeted Protein Degradation
10th June 2020 | 1.30 - 3.00 PM - BST / 2.30 PM CEST - 4.00 PM CEST
Chairman Opening & Remarks by Danette Daniels, PHD, R&D Group Leader of Functional Proteomics, Promega Corp
Hosted by Kristin Riching, Senior Scientist, Promega & William Farnaby, Team Leader In Medicinal Chemistry And Chemical Biology University of Dundee
We share your passion for science. As an expert leader in bioluminescent technologies, Promega has developed a series of tools for drug discovery and development as well as for lot release of therapeutic antibodies. Among these tools are bioassays for the characterization of biologics as well as tools for small molecule research such as NanoBRET Target Engagement, Target Identification and Target Protein Degradation. Let’s collaborate
- Why and when is a TPD approach suitable for your drug discovery project?
- What is a ‘hit’ in the context of TPD?
- Which assays can help you functionally characterize degraders and further optimize?
Our digital workshop is for drug discovery experts interested in learning more about the latest innovations in targeted protein degradation. This is a free event open to all, so why not register and benefit from the expertise of our speakers?
Danette Daniels received her B.A. from Columbia University, Ph.D. in Biophysics from Yale University, and completed a postdoctoral fellowship at Stanford University School of Medicine studying the biophysical and biochemical mechanisms of the Wnt signaling pathway. She has been at Promega Corporation for 15 years and is currently an R&D Group Leader of Functional Proteomics. She leads a team developing technologies and performing research to understand dynamic intracellular interactions within the focus areas of epigenetics, transcription, and targeted protein degradation.
William Farnaby is currently a team leader in medicinal chemistry and chemical biology at the School of Life Sciences, University of Dundee. Since 2016 he has led a multi-disciplinary team of drug discovery scientists engaged in a collaboration between Professor Alessio Ciulli and Boehringer Ingelheim. This unique collaboration model aims to discover bi-valent degraders to address areas of critical unmet medical need. William has led and progressed protein degradation projects through multiple stages of the drug discovery process and in doing so continues to contribute significantly to the advance of rational degrader design, synthesis and methods of biochemical and cellular evaluation. Prior to this William worked for 8 years at Takeda Cambridge as a senior medicinal chemist. He led collaborative programs to develop novel chemical matter to accelerate early stage CNS drug discovery and is a co-inventor of multiple clinical candidates currently under investigation.
Twitter handle: @farnaby84
Kristin Riching received her PhD in Biomedical Engineering from the University of Wisconsin – Madison, where she studied the structural and mechanical properties of collagen fibre networks and their effects on breast cancer cell migration in invasive ductal carcinoma. She joined Promega in 2014 as a postdoctoral researcher to study the pharmacology of ligand-dependent responses within the ErbB signalling network. Currently, she is a Senior Scientist developing technologies and approaches for live cell characterization of protein degradation and protein interactions within the ubiquitin proteasome pathway.